FIELD: medicine; therapy; endocrinology.
SUBSTANCE: group of inventions is intended for the treatment or prevention of vasomotor symptoms. The following is used: 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof or a composition containing the same as an agent for treating or preventing vasomotor symptoms in a subject in need of it. Also the following is provided: a method of treating or preventing vasomotor symptoms in a subject in need thereof, a method comprising administering to the subject 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof in a daily dose of 10 mg or less.
EFFECT: use of the group of inventions makes it possible to increase the effectiveness of the treatment or prevention of vasomotor symptoms.
26 cl, 7 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR TREATING AND PREVENTING VASOMOTOR SYMPTOMS | 2017 |
|
RU2768875C2 |
| S-MIRTAZAPINE FOR HOT FLASH TREATMENT | 2005 |
|
RU2396957C2 |
| TREATMENT OF GASTROPARESIS ASSOCIATED SYMPTOMS FOR WOMEN | 2012 |
|
RU2616520C2 |
| METHODS FOR TREATMENT OF DISORDERS OF CIRCADIAN SLEEP RHYTHM | 2017 |
|
RU2763493C2 |
| TREATMENT OF RENAL CELL CARCINOMA WITH LENVATINIB AND EVEROLIMUS | 2017 |
|
RU2785893C2 |
| DROSPIRENONE FOR HORMONAL REPLACEMENT THERAPY | 2005 |
|
RU2402331C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| MEDICATION FOR TREATMENT OF IRRITATE BOWELS SYNDROME WITH DIARRHEA PREVALENCE | 2007 |
|
RU2351327C2 |
| AGONISM OF 5НТ-RECEPTOR FOR TREATMENT OF DISTURBANCE OF THERMOREGULATION FUNCTION | 2003 |
|
RU2340333C2 |
| METHOD FOR ENHANCING OF TESTOSTERONE AND ANALOGOUS STEROID LEVELS IN FEMALES | 2001 |
|
RU2286787C2 |
